Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany.

Mustea, A., Oskay-Oezcelik, G., Wimberger, P., Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Sehouli, J., 2015.

European Journal of Cancer 51 (suppl 3) 548. 10.1016/S0959-8049(16)31520-9

Studie: OTILIA; Indikation: Sonstige; Jahr: 2015; Veranstaltung: ECCO (ESMO); Journal: European Journal of Cancer

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com